Acadia Pharmaceuticals | ACAD - Market Capitalization


Acadia Pharmaceuticals reported $5.07B in Market Capitalization this August of 2026, considering the latest stock price and the number of outstanding shares.





Market Capitalization Change Date
Acadia Pharmaceuticals USD 4.53B 199M Aug/2026
ALKERMES USD 7.93B 806M Aug/2026
Alnylam Pharmaceuticals USD 40.19B 3.96B Jun/2026
Biogen USD 31.9B 5B Jun/2026
BioMarin Pharmaceutical USD 11.71B 651M Aug/2026
Bristol-Myers Squibb USD 117.66B 6.17B Jun/2026
Cara Therapeutics USD 110M 80M Aug/2026
Corcept Therapeutics USD 9.33B 5.02B Jun/2026
Cytokinetics USD 9.6B 1.95B Aug/2026
Eisai JPY 1.2T 219.32B Jun/2026
Eli Lilly USD 1.11T 18.32B Aug/2026
Incyte USD 26.84B 4.19B Aug/2026
J&J USD 611.36B 32.21B Jun/2026
Neurocrine Biosciences USD 16.95B 3.7B Jun/2026
Pfizer USD 153.17B 14.73B Aug/2026
Prothena USD 516M 2M Mar/2026
Sarepta Therapeutics USD 1.5B 402M Aug/2026
Ultragenyx Pharmaceutical USD 2.12B 1.16B Aug/2026
Vanda Pharmaceuticals USD 279M 6M Dec/2024
Vertex Pharmaceuticals USD 137.33B 11.26B Aug/2026